Welcome to our dedicated page for Arcus Bioscience news (Ticker: RCUS), a resource for investors and traders seeking the latest updates and insights on Arcus Bioscience stock.
Arcus Biosciences, Inc. (NYSE: RCUS) generates frequent news as a clinical-stage, global biopharmaceutical company advancing investigational therapies for cancer, inflammatory diseases and autoimmune diseases. News about Arcus often centers on clinical trial updates for its lead programs, collaboration developments and corporate financing activities that support its pipeline.
Key oncology news items include data readouts and study milestones for casdatifan, a small-molecule HIF‑2α inhibitor being developed for clear cell renal cell carcinoma (ccRCC). Investors can follow announcements from the ARC‑20 Phase 1/1b study in late-line and early-line ccRCC, the global Phase 3 PEAK‑1 trial in immunotherapy-experienced metastatic ccRCC, and the eVOLVE‑RCC02 Phase 1b/3 study that combines casdatifan with volrustomig in first-line metastatic ccRCC. Updates often highlight progression-free survival, response rates, safety findings and the design of new cohorts or registrational strategies.
Arcus news also covers its broader oncology portfolio, including quemliclustat, a CD73 inhibitor in the PRISM‑1 Phase 3 trial for first-line metastatic pancreatic ductal adenocarcinoma, and the domvanalimab plus zimberelimab combinations in gastrointestinal and lung cancers. Coverage has included positive survival and response data from the Phase 2 EDGE‑Gastric study, as well as the later decision to discontinue the Phase 3 STAR‑221 and EDGE‑Gastric studies after an interim analysis showed no overall survival benefit over standard therapy.
On the inflammation and immunology side, Arcus issues updates on its emerging small-molecule programs targeting MRGPRX2, TNF, CCR6 and CD40L, and an anti‑CD89 antibody program. News may describe preclinical progress, selection of development candidates and plans to enter the clinic in indications such as atopic dermatitis, chronic spontaneous urticaria, rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis and systemic lupus erythematosus.
Corporate and financial news for RCUS includes public equity offerings, amendments to loan facilities, participation in major healthcare and investor conferences, and guidance on cash runway. Readers can use this news page to follow how clinical data, partnership decisions with Gilead Sciences and Taiho Pharmaceutical, and capital-raising activities shape Arcus’s development priorities over time.
Arcus Biosciences, Inc. (NYSE:RCUS) announced the granting of stock options and restricted stock units to thirteen new employees. A total of 29,050 options were granted at an exercise price of $27.31, based on the closing price on April 25, 2022. Additionally, 14,525 restricted stock units were issued. These equity awards are part of the Company’s 2020 Inducement Plan, approved in January 2020, which allows for stock grants under NYSE rules. Arcus focuses on developing innovative cancer therapies through partnerships and clinical studies.
Arcus Biosciences (NYSE:RCUS) has announced the granting of equity awards to 13 new employees. The awards include options to purchase 28,900 shares at an exercise price of $33.70 per share and restricted stock units for a total of 14,450 shares. This action is part of the company's 2020 Inducement Plan, approved in January 2020. Arcus focuses on developing innovative cancer therapies, with six investigational medicines currently in clinical studies targeting key biological pathways.
Arcus Biosciences (NYSE:RCUS) announced the granting of equity awards to eleven new employees, totaling options to purchase 30,950 shares at an exercise price of $32.98, the closing price on March 23, 2022. Additionally, restricted stock units were awarded for 15,475 shares. These grants were made under the 2020 Inducement Plan approved by the Board of Directors in January 2020. Arcus is focused on developing innovative cancer therapies, including six investigational medicines targeting various pathways.
Arcus Biosciences, Inc. (NYSE:RCUS) announced the granting of stock options and restricted stock units to 14 new employees. A total of 61,000 stock options at an exercise price of $33.03 per share and 30,500 restricted stock units were granted. These awards are part of the company's 2020 Inducement Plan approved by the Board of Directors in January 2020. Founded in 2015, Arcus focuses on developing innovative therapies for cancer treatment, with an emphasis on combination approaches targeting various biological pathways.
Arcus Biosciences (NYSE:RCUS) announced promising initial data for AB521, a HIF-2a inhibitor, suggesting it may outperform the only approved HIF-2a inhibitor. The findings were detailed at the ESMO Targeted Anticancer Therapies Congress on March 7-8, 2022. Future presentations will include PK/PD modeling for etrumadenant, quemliclustat, and zimberelimab at the ASCPT conference on March 16-18, 2022, and insights into enhancing anti-tumor immunity at AACR on April 8-13, 2022. The company is progressing with its clinical trials, particularly a Phase 1/1b study for AB521 in renal cancer.
Arcus Biosciences, Inc. (NYSE:RCUS) announced the grant of equity awards to seven new employees, totaling 20,450 stock options at an exercise price of $30.01 per share, based on the February 23, 2022 closing price. Additionally, 10,225 restricted stock units were awarded. The grants fall under the 2020 Inducement Plan approved by the Board of Directors in January 2020, complying with NYSE regulations.
Arcus is committed to developing innovative cancer therapies and has advanced multiple investigational medicines into clinical studies.
Arcus Biosciences reported strong financial results for the fourth quarter and full year 2021, highlighting a net income of $279.4 million for Q4 compared to a net loss of $51.9 million in the previous year. Revenues surged to $354.5 million, significantly up from $9.5 million year-over-year, mainly due to Gilead's collaboration. The company holds approximately $1.4 billion in cash, ensuring funding into 2026. Arcus has multiple Phase 3 studies underway for its lead drug, domvanalimab, in various cancers, indicating robust pipeline growth.
Arcus Biosciences (NYSE: RCUS), a biopharmaceutical company focused on developing cancer therapies, announced participation in two upcoming investor conferences. The first is the SVB Leerink 11th Annual Global Healthcare Conference, scheduled for February 16, 2022, at 1:20 p.m. PT, and the second is the Barclay’s Global Healthcare Conference on March 17, 2022, at 1:35 p.m. ET. Live audio webcasts will be available on the Arcus Biosciences website, and replays will be accessible for two weeks after the events.
Arcus Biosciences (NYSE:RCUS) announced the granting of stock options and restricted stock units to six new employees, totaling 64,050 shares at an exercise price of $30.30, equivalent to the closing price on February 8, 2022. Additionally, 2,025 restricted stock units were awarded. These grants were made under the Company’s 2020 Inducement Plan, approved in January 2020, complying with NYSE regulations. Founded in 2015, Arcus focuses on developing innovative cancer therapies, with six investigational medicines currently in clinical studies.
Arcus Biosciences (NYSE:RCUS) announced that its Compensation Committee granted options to purchase 38,850 shares and restricted stock units for 925 shares to six new employees. The exercise price is set at $31.75, equivalent to the closing price on January 24, 2022. The equity awards comply with the 2020 Inducement Plan approved by the Board of Directors in January 2020. Arcus Biosciences is focused on developing innovative cancer therapies and has advanced six investigational medicines into clinical studies.